Smartlens

About Smartlens

Smartlens, Inc. is a clinical-stage ophthalmic technology company developing solutions to manage glaucoma and other anterior segment eye diseases. Founded in 2015 by Savas Komban, Murat Baday, and Sevda Agaoglu, the company is headquartered in Mountain View, California. The foundational research behind its core technology originated at Stanford University and was published in Nature Medicine in 2014. Co-founder and CEO Savas Komban is a serial entrepreneur with a background in leadership at NTT DATA Business Solutions and SAP, bringing extensive experience in business innovation.

The company is addressing the limitations of traditional eye care, which relies on infrequent in-office measurements, by creating a platform for personalized and proactive disease management. Smartlens has secured $6.1 million in an oversubscribed Series A funding round led by Ambit Health Ventures, with participation from Stanford University and other venture capital firms, to advance regulatory clearance for its products. The business model appears to be focused on the development and commercialization of medical devices for the ophthalmology market, targeting eye care specialists and their patients.

Smartlens's integrated platform consists of three core components. The flagship product, miLens™, is a non-invasive, electronics-free soft contact lens that uses microfluidics to enable remote, continuous monitoring of intraocular pressure (IOP), a primary risk factor for glaucoma. Clinical results have shown a strong correlation between miLens™ measurements and the gold standard, Goldmann applanation tonometry, with 78% of its measurements falling within 2 mmHg of the standard. The second component is the Slit IQ™ platform, an AI-powered imaging system that functions as a smart slit lamp for remote eye examinations, allowing for standardized documentation and assessment of various conditions like cataracts and corneal diseases. Finally, the THERx IQ™ is a wearable device for automated and personalized micro-dosing of medication, aiming to improve treatment adherence and efficacy by delivering drugs based on real-time IOP data.